Patent · US Active

Crystalline 2-(3,5-Bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethyl-propanamide of the formula (I), their use in therapy, and process for the preparation of the same

US8796269B2 · kind B2 · utility

6Cited by

0References

9Claims

0Family size

Assignee

NeRRe Therapeutics Limited · GB

Inventors

Andrew Craig · Ashford, GB
Salima Zarah Ismail · Stevenage, GB
Ronnie Maxwell Lawrence · Stevenage, GB

Key dates

Filing date	Aug 25, 2010
Grant date	Aug 5, 2014
Priority date	—
Expiry date	Oct 3, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the compound of formula (I) in a crystalline anhydrate form,pharmaceutical formulations containing them, their use in therapy and processes for preparing the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.